ARCH Venture Fund XIII, L.P. bought $12.5M of Lyell Immunopharma (LYEL)

Executed Mar 6, disclosed Mar 9, 3 days later.

Value, as filed

$12.5M

488,090 sh × $25.61

Executed

Mar 6

the trade date, as filed

Disclosed

Mar 9

3 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

-6.9%

+0.4% from execution

Over the 21 trading sessions from the disclosed entry session (Mar 9), the stock returned -6.9% (delay-adjusted); from the execution session (Mar 6), +0.4%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

AP ARCH Venture Fund XIII, L.P. 10% owner profile →

ARCH Venture Fund XIII, L.P. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in Lyell Immunopharma, Inc. (LYEL). Across 1 priced purchase filing, the average 21-session return was +0.4% from execution and -6.9% from disclosure (delay-adjusted; derived). The largest single filing was $25.0M of LYEL (2,321,262 sh × $10.77, as filed), executed Nov 4.

The name

LYEL

Lyell Immunopharma, Inc. LYEL · Healthcare · 9 filings in 24 months ticker →

Healthcare · Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for pat…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by ARCH Venture Fund XIII, L.P. in LYEL

LYELPURCHASE Lyell Immunopharma, Inc. $25.0M
2,321,262 sh × $10.77
Exec Nov 4
Filed Nov 5 · 5:34 PM ET